OIG again expressed concern that CMS’s reimbursement methodology for drugs used in administering dialysis to end-stage renal disease (ESRD) patients may not adequately reflect the acquisition costs of the drugs, according to a recent report by the Office of Inspector General’s Office of Evaluations and Inspections. Building upon concerns expressed in a 2010 report that
